Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Begins Phase I Trial of TTR Amyloidosis Drug

Premium

Alnylam Pharmaceuticals announced this week that it has begun dosing patients in a phase I trial of its transthyretin-mediated amyloidosis drug ALN-TTR01.

The study is being conducted in Portugal, Sweden, and the UK and will enroll about 28 patients with the disease.

The primary objective of the trial is to evaluate the safety and tolerability of a single dose of intravenous ALN-TTR01, with patients being enrolled into five sequential cohorts of increasing doses ranging from 0.01 to 0.4 mg/kg, Alnylam said. Secondary objectives include characterization of plasma and urine pharmacokinetics of ALN-TTR01, and assessment of pharmacodynamic activity based on measurements of circulating TTR serum levels.

TTR amyloidosis is a hereditary, systemic disease caused by a mutation in the transthyretin gene. ALN-TTR01 is a systemically delivered siRNA designed to inhibit both mutant and wild-type TTR. It is delivered using partner Tekmira Pharmaceutical's stable nucleic acid-lipid particle technology.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.